Table 2.
The list of the top 20 most cited papers within our dataset.
| References | Publication year | Journal | Title | DOI | Citations |
|---|---|---|---|---|---|
| Kurtzke et al. (20) | 1983 | Neurology | Rating neurologic impairment in multiple sclerosis. An expanded disability status scale (EDSS) | 10.1212/WNL.33.11.1444 | 10,052 |
| Poser et al. (22) | 1983 | Ann Neurol | New diagnostic criteria for multiple sclerosis: Guidelines for research protocols | 10.1002/ana.410130302 | 6,770 |
| Polman et al. (23) | 2011 | Ann Neurol | Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria | 10.1002/ana.22366 | 5,428 |
| McDonald et al. (24) | 2001 | Ann Neurol | Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis | 10.1002/ana.1032 | 4,985 |
| Polman et al. (25) | 2005 | Ann Neurol | Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” | 10.1002/ana.20703 | 3,732 |
| Krupp et al. (38) | 1989 | Arch Neurol | The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus | 10.1001/archneur.1989.00520460115022 | 3,218 |
| Trapp et al. (27) | 1998 | N Engl J Med | Axonal Transection in the Lesions of Multiple Sclerosis | 10.1056/NEJM199801293380502 | 3,032 |
| Lucchinetti et al. (28) | 2000 | Ann Neurol | Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination | 10.1002/1531-8249(200006)47:6 <707::AID-ANA3>3.0.CO;2-Q | 2,157 |
| Polman et al. (26) | 2006 | N Engl J Med | A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis | 10.1056/NEJMoa044397 | 2,094 |
| Jacobs et al. (34) | 1996 | Ann Neurol | Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) | 10.1002/ana.410390304 | 2,004 |
| Duquette et al. (35) | 1993 | Neurology | Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group | 10.1212/wnl.43.4.655 | 1,996 |
| Lennon et al. (39) | 2004 | Lancet | A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis | 10.1016/S0140-6736(04)17551-X | 1,940 |
| Wingerchuk et al. (40) | 2006 | Neurology | Revised diagnostic criteria for neuromyelitis optica | 10.1212/01.wnl.0000216139.44259.74 | 1,842 |
| Liddelow et al. (29) | 2017 | Nature | Neurotoxic reactive astrocytes are induced by activated microglia | 10.1038/nature21029 | 1,761 |
| Maurano et al. (30) | 2012 | Science | Systematic localization of common disease-associated variation in regulatory DNA | 10.1126/science.1222794 | 1,708 |
| Sawcer et al. (31) | 2011 | Nature | Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis | 10.1038/nature10251 | 1,707 |
| Ebers et al. (33) | 1998 | Lancet | Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis | 10.1016/S0140-6736(98)03334-0 | 1,691 |
| Kappos et al. (36) | 2010 | N Engl J Med | A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. | 10.1056/NEJMoa0909494 | 1,689 |
| Chen et al. (32) | 1994 | Science | Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis | 10.1126/science.7520605 | 1,621 |
| Holick et al. (41) | 2004 | Am J Clin Nutr | Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease | 10.1093/ajcn/80.6.1678S | 1,582 |